当前慢性乙型肝炎感染的治疗包括干扰素和核苷酸类药物,一般不降低HBsAg的产生,这与慢性乙型肝炎感染的不良预后相关。来自美国斯克里普斯研究所的Billioud等对已用于肝靶向治疗抑制HBsAg产生和临床前期病毒血症的反义寡核苷酸技术的效果进行了评估。先导反义寡核苷酸已在体外证实其特征,随后在体内和 The current treatment of chronic hepatitis B infection includes interferons and nucleotide drugs, generally does not reduce the production of HBsAg, which is associated with poor prognosis of chronic hepatitis B infection. Billioud et al from the Scripps Research Institute in the United States evaluated the efficacy of antisense oligonucleotide technology that has been used in liver-targeted therapies to inhibit HBsAg production and preclinical viremia. The leader antisense oligonucleotide has been characterized in vitro, followed by in vivo and in vivo